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Abstract: Cardiovascular disease (CVD) is largely the product of interactions among 
modifiable risk factors that are common in developed nations and increasingly of concern in 
developing countries. Hypertension is an important precursor to the development of CVD, and 
although detection and treatment rates have improved in recent years in some jurisdictions, 
effective strategies and policies supporting a shift in distribution of risk factors at the popula-
tion level remain paramount. Challenges in managing cardiovascular health more effectively 
include factors at the patient, provider, and system level. Strategies to reduce hypertension 
and CVD should be population based, incorporate multilevel, multicomponent, and socioen-
vironmental approaches, and integrate community resources with public health and clinical 
care. There is an urgent need to improve monitoring and management of risk factors through 
community-wide, primary care-linked initiatives, increase the evidence base for community-
based   prevention strategies, further develop and evaluate promising program components, and 
develop new approaches to support healthy lifestyle behaviors in diverse age, socioeconomic, 
and   ethnocultural groups. Policy and system changes are critical to reduce risk in populations, 
including legislation and public education to reduce dietary sodium and trans-fatty acids, food 
pricing policies, and changes to health care delivery systems to explicitly support prevention 
and management of CVD.
Keywords: risk factors, blood pressure determination, community health services, community 
health planning, public health practice
The burden of cardiovascular disease
Cardiovascular diseases (CVDs) are largely the product of interactions among several 
modifiable risk factors that are too common in developed nations and increasingly of 
concern in developing countries. Effective, integrated health promotion programs and 
policies are our best tools to counteract the epidemics of obesity, diabetes, heart dis-
ease, and stroke that are emerging worldwide.1 Despite accumulation of evidence and 
established health care infrastructure, CVD remains a major public health   challenge in 
North America and Western Europe. Furthermore, dramatic increases in   cardiovascular 
risk factors and corresponding increases in prevalence and incidence of CVD have 
occurred in countries experiencing rapid development such as China, Thailand and 
Mexico.2 CVD accounted for 30% of an estimated 58 million deaths worldwide from 
all causes in 2005.3 Shifting the focus to an “upstream” approach of primary prevention 
integrated across different sectors and policies rather than a “downstream” approach Risk Management and Healthcare Policy 2010:3 submit your manuscript | www.dovepress.com
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of medical care has the potential to decrease the individual, 
societal, and economic burden of CVD.
Hypertension and CVD
Hypertension is a key factor in the development of CVD and 
stroke,4 and people with other chronic conditions such as dia-
betes are at increased risk of hypertension complications.5,6 
The global burden of blood pressure (BP)–related disease 
is substantial; over 54% of stroke, 47% of ischemic heart 
disease, and 13.5% of all deaths worldwide were attributed 
to high BP in 2001.7 The risk of developing hypertension 
increases with age such that the residual risk (lifetime cumu-
lative incidence not adjusted for competing causes of mortal-
ity) of developing hypertension for middle-aged individuals 
is 90%.8 The recent Canadian Health Measures Survey esti-
mated that 1 in 5 Canadian adults (20%) had hypertension 
and another 20% had prehypertension (defined as systolic 
BP 120–139 mm Hg or diastolic BP 80–89 mm Hg).9 In 
the United States, approximately 73 million adults have 
hypertension.10 Previous population-based surveys found 
that 60% of the US adult population is affected, 27% with 
hypertension and 31% with prehypertension.11 The age- and 
sex-adjusted prevalence of hypertension was found to be 
higher in six European countries at 44% among adults aged 
19–64 years, using the threshold of 140/90 mm Hg.12
Hypertension is costly to health care systems, contributing 
to the costs of treating CVD and stroke. Globally, the cost 
attributed to suboptimal BP (systolic BP . 115 mm Hg) was 
estimated at US$372 billion in 2001, representing about 10% 
of overall health care expenditures.13 Conversely, complete 
control of high BP over a 10-year period was estimated to 
yield a savings of nearly $1 trillion worldwide.13
The relationship between BP and CVD risk is strong, 
continuous, and independent of other risk factors.14 There 
is strong evidence that reduction in BP is associated with 
highly significant reductions in morbidity and mortality from 
CVD and stroke, as well as all-cause mortality.15,16 Evidence 
from randomized controlled trials supports promotion of 
healthy lifestyle choices to reduce BP, including adopting a 
weight-reducing diet, regular exercise, smoke-free environ-
ment, and restricted alcohol and sodium intake.17 There are 
also numerous cost-effective pharmacologic therapies to 
reduce BP.18
Despite concerted efforts to establish and improve 
adherence to guidelines and best practices for the treatment 
of high BP in recent decades,19–22 many individuals with 
hypertension remain undiagnosed or undertreated and at 
risk of CVD morbidity and mortality.23,24 In Canada and 
the United States, prevalence of hypertension has remained 
largely unchanged over the last decade, although rates of 
treatment have improved.9,25 The Canadian Health Measures 
Survey (2007–2009) showed that an estimated 83% of adults 
with hypertension were aware of their condition, 80% were 
taking medication, and 66% were controlled,9 compared 
with the 16% treated and controlled in a previous national 
survey (1985–1992), and 34% remain uncontrolled.26 In the 
United States, BP control improved by 8.1% (29.2%–36.8%) 
in 2003–2004 compared with 1999–2000.25 More recent 
estimates indicate that 43% of Americans treated for hyper-
tension do not reach the targets recommended by the Joint 
National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure.27 Although the 
increase in treatment rates is promising, additional efforts 
are needed to reduce or delay incidence through lifestyle 
factors and control high BP among the substantial number of 
individuals who are not treated to recommended targets.
Challenges in the prevention  
of hypertension and CVD
Challenges in managing cardiovascular risk factors, including 
hypertension, more effectively include factors at the patient, 
health care provider, and system level. Once hypertension is 
diagnosed, BP is often not controlled to optimal levels.28,29 
Among older adults, in particular, high BP is frequently 
underdiagnosed and undertreated.26 Older patients will 
frequently present with multiple health problems, which 
may reduce attention to detecting and treating elevated 
BP. Control of elevated BP may also be limited by uneven 
clinician adoption of newer thresholds, treatment protocols, 
and lifestyle recommendations30 or by clinician uncertainty 
regarding the patient’s usual BP or the extent of medication 
nonadherence.27,31 Recommendations vary by country, with 
more aggressive treatment recommendations in Canada and 
the United States than in many Western European countries.32 
Application of lower treatment thresholds and more intensive 
treatment regimens has been shown to support better con-
trol32 and reduce the risk of CVD and stroke in populations, 
including patients aged 80 years or older.33 Nonetheless, 
health care providers may still hesitate to treat patients who 
are older or have comorbidities with sufficient intensity to 
reach recommended targets,34 even when hypertension is 
severe.35
Patients’ adherence to pharmacological antihypertensive 
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side effects of multiple therapies. Patients and health care 
providers may also disagree about the need to intensify 
treatment.27 Lifestyle modification, including dietary changes, 
maintaining a healthy body weight, and increasing physical 
activity are evidence-based recommendations for hyperten-
sion prevention and control; however, behavioral changes 
are difficult for most people to achieve and maintain36 and 
are frequently underutilized in clinical practice.37
Dietary factors
The link between salt intake and increased BP has been well 
established through ecological, population, and prospective 
cohort studies and intervention trials,38 yet sodium consump-
tion remains a particular concern in relation to increasing BP 
in Western populations. In the United States, 87% of adults are 
estimated to consume excess daily levels of salt (.100 mmol 
of sodium, .2,400 mg of sodium, or .6,000 mg of salt 
[sodium chloride]).39 It is difficult to accurately calculate 
sodium intake because a large proportion of our dietary salt 
is added in the processing and manufacturing of foods and 
in the fast-food industry; it is estimated that 75% of dietary 
sodium is added during food processing.40
Factors, which characterize the developed world and 
contribute to obesity, include a largely sedentary lifestyle, 
industrialization of food production and processing, perva-
sive retailing and marketing strategies, and environments not 
conducive to healthy lifestyle choices.41 Similar patterns of 
increasing obesity rates are seen in developing countries 
that have undergone rapid economic development leading to 
adoption of a Western lifestyle characterized by low physical 
activity and high consumption of inexpensive, energy-dense 
food.42 The rise in obesity is difficult to counteract without 
attention to the wider social, socioeconomic, and environ-
mental factors that constitute barriers to implementation of 
healthy lifestyle changes.
Strategies to reduce  
hypertension and CVD
To address the complex and multilevel challenges limiting the 
optimal management of CVD risk worldwide, the strategies 
used will need to span the clinical and public health contexts 
and target patient-, provider-, and system-level factors.
Out-of-office BP measurements used to augment in-office 
data have potential to improve hypertension detection and 
management by reducing both the observer effects43 and 
the potential effects of the clinical setting.44–47 Ambulatory 
monitoring, previously the gold standard for BP assessment, 
is neither practical nor affordable for wide-scale application 
or monitoring over time and is inconvenient for patients.
Monitoring BP at home, with proper use of approved 
devices, is widely recommended48 and supported by evidence 
demonstrating the potential for improved control. A   systematic 
review of the literature on home BP measurement concluded 
that it yields lower values than office measurement, with 
differences in systolic BP that increase with age and the level 
of BP measured in office.49 Home monitoring also correlates 
better with target organ damage and cardiovascular mortality 
than office measurement, enables prediction of sustained 
hypertension in patients with borderline hypertension, 
identifies normotensive patients with greater certainty, and 
can better assess drug efficacy.49
Clinic and community approaches  
to increase treatment and control  
of hypertension
A 2010 report on hypertension prevention and control in the 
United States pointed to a failure to translate public health and 
clinical knowledge into effective programs for prevention, treat-
ment, and control of high BP as the reason for the persistence of 
hypertension as a “neglected disease” and emphasized the need 
for policy and system change to bridge public health and clinical 
care.50 Key recommendations include the following: a stronger 
focus on primary prevention through interventions to help 
reduce obesity, support healthy eating (decrease sodium intake 
and increase potassium intake) and increase physical activity; 
increased monitoring and reduction of sodium intake to meet 
current dietary guidelines; providing community-based support 
for individuals with hypertension through community health 
workers trained in dietary and physical activity counseling; and 
improved surveillance and reporting of hypertension to measure 
progress over time (including understudied populations: 
children, racial and ethnic minorities, the elderly, and selected 
socioeconomic groups).50
A review of effective strategies for BP control   emphasized 
the value of strategies carried out at the community level.51 
Community-based monitoring using an automated device is a 
promising approach to increase the number and   accuracy of BP 
readings used in diagnosing and   managing hypertension.45,52 
Community programs can also provide opportunities for 
education and support for lifestyle modification.
Dietary factors
Since 1996, the United Kingdom’s Consensus Action on Salt 
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health campaign to reduce salt added to foods, educate the 
public about the risks associated with excess salt, and trans-
late evidence into public health policy.38 A detailed strategy 
with a target for salt reduction of 40% was implemented in 
2003 based on measurement using 24-hour urinary sodium 
output,53 which showed that the average salt intake of 9.5 g/d 
required a reduction of 3.5 g, specifically in the amount of 
salt added in the food industry (7.6–4.6) and in cooking/
table use (1.4–0.9). Salt intake was reduced from 9.5 to 
8.6 g/d during the period of 2003–2008,54 and the targets 
have been revised to ensure that salt intake will be reduced 
to 6 g/d by 2012.55
Gradual reduction in salt added to foods (10%–20% at 
1–2 year intervals) is a promising strategy, because such 
changes are not detectable by human salt taste receptors56 
and do not pose preparatory or safety issues. A recent report 
by the Institute of Medicine stated that because the vast 
majority of Americans’ sodium intake comes from salt added 
during preparation or processing of purchased food, a federal 
regulatory strategy will be implemented to incrementally 
reduce the maximum amount of salt that can be added to 
foods, beverages, and meals and effectively regulate salt as 
an additive with known risks.57 A regulatory strategy is a 
necessary step after 4 decades of public education campaigns 
and pressure on the food industry to voluntarily cut sodium 
have failed to substantially reduce sodium intake.57
Similarly, several European countries and selected 
jurisdictions in North America have implemented bans on 
trans fats, which have been shown to increase risk of CVD 
and stroke,58 specifically in prepared foods at food service 
outlets.
Population approaches for chronic 
disease prevention
There is no single solution to the challenge of CVD and 
its toll on populations and health care systems around the 
world. However, there is emerging consensus that for chronic 
disease prevention and management, population-based strate-
gies are much more effective than those aimed at individuals. 
We see this in the World Health Organization’s efforts to 
promote the use of multiple fiscal and educational policies as 
the first-line approach for CVD reduction in all settings.59
Health and longevity are influenced not only by indi-
viduals’ characteristics but also by the characteristics of 
the communities in which people work and live and their 
wider societal circumstances. A population or public 
health approach to preventing disease acknowledges the 
importance of social and environmental factors in shaping 
health behaviors and access to health services. There is 
mounting empirical evidence to support the use of a broad 
approach for stroke and CVD prevention campaigns, through 
population-wide, community-level interventions that would 
enable residents to learn about and engage in healthier 
behaviors.60–64 Strategies include organizing communities 
to address health issues, educating residents via mass media 
and direct approaches, providing opportunities for screening 
risk factors, and changing local environments to promote 
healthier lifestyles.62,65
Awareness of the importance of interrelated social and 
environmental factors in shaping lifestyle behaviors has 
spurred efforts to make it easier for the public to make healthy 
choices, such as promoting “walkable” communities66 and 
increasing local availability of healthy foods. Behaviors such 
as smoking, poor diet, and lack of exercise are examples of 
modifiable risk factors for CVD that are frequently affected 
by broader interrelated factors, including socioeconomic 
status, ethnicity, neighborhood characteristics, and elements 
of the built environment.67–69 Recognition of the health 
system as an important socioenvironmental determinant 
has prompted interest in how organizations that develop 
and deliver chronic disease prevention and healthy lifestyle 
programs within health systems can contribute to reducing 
the chronic disease burden.70
Foremost among strategies is the need to adopt a 
population-based approach, to move away from an individual 
medical focus, to facilitate broader education, and to monitor 
linkage to treatment at the community or population level. 
Strategies that encompass a population perspective while also 
addressing individual determinants of risk are promising.71 
An example is community-based interventions that aim to 
decrease the burden of CVD by shifting the distribution 
of risk factors at the population level, which may include 
reducing the proportion of a population with high BP.72 
Health interventions based on community organization and 
development models emphasize partnerships, collaboration, 
and community mobilization to maximize coverage and 
capitalize on diffusion effects.73
Early population health efforts in developed countries, 
from the 1970s to 1990s, focused primarily on screening. 
The   conditions for implementing screening programs included 
weighing the potential benefits and harms of screening, estab-
lishing an expectation that early detection would yield better 
outcomes, and ensuring that follow-up is appropriate and 
feasible.74–76 More recent work in community-level health Risk Management and Healthcare Policy 2010:3 submit your manuscript | www.dovepress.com
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promotion has incorporated multilevel, multicomponent, 
socioenvironmental approaches that include medical, 
behavioral, and community development strategies.77 Such 
programs use many points of leverage (eg, individuals, orga-
nizations, social networks, communities, and policymakers) 
and seek an optimal blend of strategies to effect change in 
a community.78
Cardiovascular health programs  
in communities
Several large-scale community-based CVD prevention cam-
paigns showed promising results;79,80 however, subsequent 
efforts have produced only modest, inconsistent effects 
on risk factors without any significant effects on health 
outcomes.81–83 Much has been written about the varying 
success of major cardiovascular prevention initiatives, such 
as the Franklin, Minnesota, North Karelia, and Stanford 
projects.80,84–86 Some smaller-scale community interven-
tions based in primary care,87,88 including nurse-mediated 
interventions,89 have shown reductions in risk factors.
Although community-based CVD prevention interventions 
have the potential to shift the burden of risk in populations, 
the effectiveness of directly assessing BP for elevated 
levels has yet to be established. In fact, although community-
based BP screening programs have a long history, relatively 
few of them have been rigorously evaluated.
integration of community resources
Multidisciplinary teams are increasingly favored as a means of 
delivering comprehensive primary care. Teams might include, 
eg, family physicians, nurse practitioners, social workers, 
dieticians, pharmacists, and other allied health professionals. 
A systematic review of controlled trials examining quality 
improvement interventions for hypertension management 
found that interdisciplinary team-based care was the only 
strategy that significantly improved BP.90 Further examination 
of the potency of team-based care interventions involving 
pharmacists or nurses concluded that team-based care was 
associated with improved BP control and that specific 
components, such as pharmacist-recommended medication 
to physicians or counseling about lifestyle modification, 
appeared to determine the potency of the intervention.20
Pay-for-performance initiatives
Additional system-level interventions include “pay-for-
  performance” schemes to encourage physicians to meet 
targets for optimal care delivery. Although programs are 
established or in development in the United Kingdom, 
United States,91–93 Canada,94 Australia,95 Germany,96 the 
Netherlands,97 New Zealand,98 and elsewhere, research to 
date examining the effectiveness of financial incentives for 
health care providers in maximizing delivery of preventive 
care services or chronic disease management is limited, 
inconclusive, and difficult to generalize to other settings.
Provider-incentive approaches may also have value 
in improving management of chronic disease. A study in 
  England to determine the effect of a pay-for-performance 
scheme on the quality of care of patients with asthma, 
  diabetes, or coronary heart disease in family practice found 
that the rate of improvement in the quality of care increased 
for asthma and diabetes (P , 0.001) but not for heart 
disease.99 The scheme accelerated an underlying trend of 
improvements in quality of care for two conditions; however, 
the gains reached a plateau after 1 year, once targets were 
reached, with improvement in diabetes care continuing at the 
preintervention rate.99 An ambitious pay-for-performance 
program specifically for management of hypertension in the 
United Kingdom has shown that generous financial incen-
tives are associated with meeting performance targets for 
aspects of care among patients with hypertension; however, 
much of this achievement may be attributable to coexisting 
quality improvement initiatives.100 As pay-for-performance 
approaches gain momentum, it is important to note the 
emergence of unanticipated outcomes, such as reductions 
in continuity of care99 or other aspects of quality that may 
result from valuing what can be measured in patient care over 
what cannot, and the need for multilayered and sustainable 
programs to achieve improvements over the long term.101
electronic medical or health records
A range of electronic systems and tools have been inves-
tigated for effectiveness in improving management of 
chronic diseases, including decision support systems such 
as drug-dosing systems and computer-generated reminder 
systems for preventive care services. Still, research on the 
most effective implementation strategy for guideline-based 
decision support systems is lacking. Two recent systematic 
reviews of electronic guideline-based clinical decision sup-
port systems in ambulatory care settings concluded that there 
is little or mixed evidence for the effectiveness of electronic 
multidimensional guidelines.102,103
Nonetheless, the increasing implementation of electronic 
medical records (EMRs) or electronic health records is 
expected to facilitate new approaches to enhance detection Risk Management and Healthcare Policy 2010:3 submit your manuscript | www.dovepress.com
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and management of chronic disease, including hypertension. 
Although the effect of EMR use in primary care on quality 
measures has been negligible in general, there is some evidence 
to suggest that the availability and use of specific EMR 
components or features may improve delivery of certain pre-
ventive care services.104 This finding supports a more tailored 
approach to the development and implementation of EMRs. 
It seems likely that electronic data capture, including capabili-
ties for disease registries, can provide opportunities for quality 
improvement and policy making to meet local needs.
Multilevel partnerships
In the United States, the Institute of Medicine is calling for 
resources to implement a broad suite of promising population-
based policy and system approaches at the federal, state, 
and local levels to combat hypertension.50 In particular, the 
Division of Heart Disease and Stroke Prevention is tasked 
with developing programs using community health workers 
for deployment in high-risk communities, with appropriate 
linkage to primary care services.50
Multidisease focus
Given that a common set of risk factors is implicated in 
multiple chronic diseases, similar strategies are expected to 
be important for their prevention, detection, and manage-
ment of a multitude of diseases and conditions. Public health 
programs are also aiming to address risk factors common 
to multiple major noncommunicable diseases.105 Health 
systems research has led to the development of theoretical 
models that help explain how various components of multi-
faceted programs work to improve the health of community 
members. For example, Wagner’s chronic care model106 
posits that improvement in care requires an approach that 
incorporates patient-, provider-, and system-level interven-
tions. This model has been expanded to include addressing 
risk behaviors in primary care, with an emphasis on linking 
community-based programs and patient self-management 
support. The outcome has been the improved care at both 
the population and individual levels.107
The broader value of community-based health initiatives 
is that learning and infrastructure can be applied to address 
other chronic diseases, specifically community or population 
approaches, such as community mobilization and partner-
ship with care providers, accurate direct assessment of risk 
factors, and delivery of peer education. Additionally, a com-
mon toolbox of methodological approaches for evaluation 
can be applied to the development and evaluation of diverse 
interventions. This is particularly important in establishing 
the reach, effectiveness, scalability, and generalizability of 
programs and the contributions of specific components.
Socioenvironmental approaches
The need to focus on primary and secondary prevention 
is important, given the preponderance of evidence for risk 
reduction through lifestyle modification and pharmacologic 
treatment. There is a need to go beyond individual lifestyle 
modification to address more fundamental determinants of 
health. Interventions to promote to healthier lifestyles have 
generally been limited in scope and not very successful in the 
longer term, mainly because of the difficulty in addressing 
the broader societal factors influencing behaviors.108–110 
A multilevel approach to prevention is essential; eg, the 
framework proposed by Sacks et al111 to address “upstream” 
policies to make healthy eating and physical activity easier, 
“midstream” policies to influence population behaviors, and 
“downstream” policies to support health services and clinical 
care. It is particularly difficult to intervene in food production, 
processing, and marketing, yet this is where the bulk of excess 
sodium, fat, and calories enter the food supply. Achieving a 
population-level reduction in the risk of metabolic disease 
may also require a paradigm shift from commercial aspects 
of food production to the wider social, cultural, economic, 
and political significance of dietary habits.112
Economic strategies are another avenue for influencing 
food choices. To date, studies on food pricing policies, such 
as modest additional taxes on less healthy, energy-dense 
foods or subsidies on healthier choices, have not shown sig-
nificant changes in body mass index or obesity rates.110 More 
substantive pricing differences are likely to have a greater 
effect; however, implementing such policies is difficult, given 
the opposition of the fast-food industry and many consumers 
who value their freedom of choice.
Within closed systems such as schools and workplaces, 
taxing or subsidizing food choices has shown greater prom-
ise in influencing food behavior.113 Localized initiatives to 
remove sugar-sweetened soft drinks and other junk food 
from schools and hospitals, or in the vicinity of schools, have 
been implemented; however, little research data are avail-
able evaluating the effectiveness of these strategies. Further 
research is needed to determine the effectiveness of fiscal 
pricing interventions in combating obesity rates.114
The physical and built environment certainly plays a role 
and has been well examined in relation to health. Substantial 
gains in community health will require structural changes in Risk Management and Healthcare Policy 2010:3 submit your manuscript | www.dovepress.com
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urban planning (ie, “walkable” communities), transportation, 
public safety, education, and health promotion.
Conclusion
After decades of investment of health care and research dollars 
to better understand and combat vascular disease, the persis-
tent challenges of hypertension, CVD, and stroke worldwide 
point to the complexity of the problem and underline the need 
for resourceful and coalescent prevention strategies. Despite 
the large number of community-based CVD or BP screening 
programs that have been described in the literature over the 
last 30 years, relatively few of them have been well evaluated 
or scaled up in a sustainable manner at the population level.
Although a number of approaches appear promising, 
evidence from well-designed trials is generally lacking, and 
most interventions are not evaluated at the population level. 
Implementing population approaches requires substantial 
commitment and resources. On-the-ground programs should 
be evaluated using rigorous methodology to increase the evi-
dence base for community-based or population-based CVD 
and stroke prevention. This can be achieved through programs 
of research that focus on both development and evaluation of 
interventions within each implementation. Where possible, it 
is important to look at testing individual components of inter-
ventions and effects at the population level. This will allow 
further development of promising components, such as lay 
health educators, community mobilization, and other outreach 
strategies, linkage to primary care, and accessing groups that 
are underserviced or underresearched.
Further, by recognizing essential aspects vs flexible aspects 
of health promotion interventions, we can expand the “toolbox” 
of effective approaches and adapt programs for implementation 
in diverse communities or municipalities. Continued research 
should prioritize the generation and use of community-specific 
health data through primary care-linked initiatives. Integrated 
collection of data on hypertension and other CVD and stroke 
risk factors in communities can aid in surveillance of chronic 
disease in populations and public health planning.
Because shifting risk levels in populations is a complex 
challenge, developing new approaches to support dietary and 
physical activity modification in diverse age, socioeconomic, 
and ethnocultural groups is critical. Effective strategies 
are likely to vary, according to the needs and preferences 
of populations. Addressing the complex determinants of 
lifestyle behaviors will also require increased cross-linkages 
of health care with other government sectors to effect changes 
in urban planning and public services to aid health. Balancing 
the funding and infrastructure for primary and secondary 
prevention of CVD and stroke is important, given the wide-
spread and well-established risk factors and the potential 
health system savings in treating “downstream” illness.
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